Skip to main content

New vaccination therapies for lung cancer

Objective

The aim of this project is to develop new vaccination approaches for the highly needed treatment of lung cancer. Lung carcinoma is the number one killer amongst cancer patients, for which no adequate treatment exists. With conventional therapy, median survival for the subtype of small cell lung cancer (SCLC) is 15 months for limited-stage disease and 9 months for extensive-stage disease, whereas long-term survival is very low.

Major obstacles to the successful treatment and eradication of lung cancer are late diagnosis, highly metastatic behaviour, resistance to chemotherapy and the impossibility to surgically remove all cancer cells. In principle, cancer vaccines are a most promising approach for the treatment of cancer in general and lung cancer in particular. Major obstacles in the development of a successful vaccine are the lack of cancer specific antigens to be targeted and the lack of tools to evaluate immunotherapy based on such targets.

Call for proposal

FP6-2002-SME-1
See other projects for this call

Funding Scheme

Cooperative - SMEs-Co-operative research contracts

Coordinator

MUBIO PRODUCTS BV
Address
Oxfordlaan 70
Maatricht
Netherlands

Participants (4)

CIRES GMBH
Germany
Address
Emil-figge Strasse 76A
Dortmund
MEDICAL PROTEOM- CENTER, RUHR-UNIVERSITY BOCHUM
Germany
Address
Universitaetsstrasse 150
Bochum
ONYVAX LIMITED
United Kingdom
Address
St. Georges Hospital Medical School, Cranmer Terrace
London
UNIVERSITEIT MAASTRICHT/RESEARCH INSTITUTE GROWTH & DEVELOPMENT
Netherlands
Address
Universiteitssingel 50
Maastricht